ClinicalTrials.gg
CompletedNCT04571424Updated Apr 18, 2023

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB133 (Dapirolizumab Pegol) in Healthy Japanese and Caucasian Participants

A Phase 1 interventional study of BIIB133 (Dapirolizumab pegol) and Placebo in Healthy Volunteers, sponsored by Biogen. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-18.

Sponsored by Biogen · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2021, 5 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The primary objective of the study is to assess the safety and tolerability of a single intravenous (IV) dose of dapirolizumab pegol (DZP) in Japanese healthy study participants compared with those of Caucasian healthy study participants.

The secondary objectives of the study are to assess the pharmacokinetic(s) (PK) of a single IV dose of DZP in Japanese and Caucasian healthy study participants, to evaluate ethnic sensitivity on the PK of DZP between body weight- and gender-matched Japanese and Caucasian healthy study participants and to evaluate the immunogenicity of a single IV dose of DZP in Japanese and Caucasian healthy study participants.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.

Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Negative polymerase chain reaction (PCR) test result for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) within 14 days of Day -1 (inclusive).
  • Japanese study participant has both biological parents and all 4 grandparents of Japanese descent and, if living outside of Japan for more than 5 years, must maintain a Japanese diet.
  • Caucasian study participant has both biological parents and all 4 grandparents of Caucasian descent.
  • Have a body weight between 50 and 90 kilograms (kg) (inclusive) and (BMI) between 18.0 and 26.0 kilograms per meter square (kg/m\^2) (inclusive) at the Screening Visit.

Key Exclusion Criteria:

  • History of any cardiac, endocrine, gastrointestinal, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, or renal disease, or other major disease, as determined by the Investigator.
  • Have undergone major surgery in the last 6 months or plans to undergo elective major surgery during the study period.
  • Have a known to any components or of DZP including polyethylene glycol (PEG).
  • Have received any prescription or nonprescription medicines including over-the-counter remedies and herbal and dietary supplements within 14 days or 5 half-lives of the respective drug, whichever is longer, other than acetaminophen and antihistamines.
  • Current enrollment in any other drug, biological, device, or clinical study, or treatment with an drug or approved therapy for investigational use within 30 days prior to Day -1, or 5 half-lives, whichever is longer.
  • History of chronic, recurrent, or recent (within 6 months prior to Screening) severe infection and/or at risk for severe infection, as determined by the Investigator.
  • Have symptoms consistent with SARS-CoV-2 infection, per the judgement of the Investigator, within 14 days prior to Day -1, including but not limited to fever (temperature > 37.5 degree Celsius [°C]), sore throat, new and persistent cough, breathlessness, or loss of taste or smell.
  • Have close contact within 14 days prior to Day -1 with a SARS-CoV-2 (+) individual. Close contact is defined as (1) being within 6 feet of an infected individual (as confirmed via laboratory assessment) for at least 15 minutes within 2 days of symptom onset or (2) being within 6 feet of an asymptomatic infected individual for at least 15 minutes within 2 days of that asymptomatic individual undergoing specimen collection for SARS-CoV-2 testing.
  • Clinically significant abnormal laboratory test result values, as determined by the Investigator, at Screening or Day -1.
  • Have received any live/attenuated vaccination within 6 weeks prior to Visit 2 (Day 1) or plans to receive any live/attenuated vaccination within 120 days after the dose of study treatment.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Cohort 1: BIIB133 Dose 1

    Participants will receive single IV infusion of BIIB133 Dose 1.

    Drug: BIIB133 (Dapirolizumab pegol)

  • Experimental
    Cohort 2: BIIB133 Dose 2

    Participants will receive single IV infusion of BIIB133 Dose 2.

    Drug: BIIB133 (Dapirolizumab pegol)

  • Placebo comparator
    Cohort 1-2: Placebo

    Participants will receive single IV infusion of matching placebo to BIIB133.

    Drug: Placebo

Interventions

  • Administered as specified in the treatment arm

    Also known as: DZP

  • DrugPlacebo

    Administered as specified in the treatment arm

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. An SAE is any untoward medical occurrence that at any dose results in death, places the participant at immediate risk of death, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in a birth defect.

    Time frame: Up to Day 120

Secondary outcomes

  1. Plasma BIIB133 Concentration

    Time frame: Up to Day 120

  2. Area under Concentration-Time Curve from Time 0 to Infinity (AUCinf) of BIIB133

    Time frame: Up to Day 120

  3. Area under Concentration-Time Curve from Time 0 to Time t (AUC0-t) of BIIB133

    Time frame: Up to Day 120

  4. Maximum Observed Concentration (Cmax) of BIIB133

    Time frame: Up to Day 120

  5. Time to Reach Maximum Observed Concentration (Tmax) of BIIB133

    Time frame: Up to Day 120

  6. Elimination Half-life (t½) of BIIB133

    Time frame: Up to Day 120

  7. Clearance (CL) of BIIB133

    Time frame: Up to Day 120

  8. Volume of Distribution (Vd) of BIIB133

    Time frame: Up to Day 120

  9. Percentage of AUCinf Obtained by Extrapolation (AUCextr%) of BIIB133

    Time frame: Up to Day 120

  10. Area under Concentration-Time Curve from Time 0 to Infinity Normalized by Dose (AUCinf/Dose) of BIIB133

    Time frame: Up to Day 120

  11. Area under Concentration-Time Curve from Time 0 to Time t Normalized by Dose (AUC0-t/Dose) of BIIB133

    Time frame: Up to Day 120

  12. Maximum Observed Concentration Normalized by Dose (Cmax/Dose) of BIIB133

    Time frame: Up to Day 120

  13. Plasma Polyethylene Glycol (PEG) Concentration

    Time frame: Up to Day 120

  14. AUCinf of PEG

    Time frame: Up to Day 120

  15. AUC0-t of PEG

    Time frame: Up to Day 120

  16. Cmax of PEG

    Time frame: Up to Day 120

  17. Tmax of PEG

    Time frame: Up to Day 120

  18. t½ of PEG

    Time frame: Up to Day 120

  19. AUCextr% of PEG

    Time frame: Up to Day 120

  20. AUCinf/Dose of PEG

    Time frame: Up to Day 120

  21. AUC0-t/Dose of PEG

    Time frame: Up to Day 120

  22. Cmax/Dose of PEG

    Time frame: Up to Day 120

  23. Urine PEG Concentration

    Time frame: Up to Day 120

  24. Ratio of AUCinf of BIIB133 between Japanese and Caucasian Participants

    Time frame: Up to Day 120

  25. Ratio of AUC0-t of BIIB133 between Japanese and Caucasian Participants

    Time frame: Up to Day 120

  26. Ratio of Cmax of BIIB133 between Japanese and Caucasian Participants

    Time frame: Up to Day 120

  27. Ratio of t½ of BIIB133 between Japanese and Caucasian Participants

    Time frame: Up to Day 120

  28. Ratio of CL of BIIB133 between Japanese and Caucasian Participants

    Time frame: Up to Day 120

  29. Ratio of Vd of BIIB133 between Japanese and Caucasian Participants

    Time frame: Up to Day 120

  30. Ratio of AUCinf/Dose of BIIB133 between Japanese and Caucasian Participants

    Time frame: Up to Day 120

  31. Ratio of AUC0-t/Dose of BIIB133 between Japanese and Caucasian Participants

    Time frame: Up to Day 120

  32. Ratio of Cmax/Dose of BIIB133 between Japanese and Caucasian Participants

    Time frame: Up to Day 120

  33. Number of Participants with Anti-BIIB133 Antibodies

    Time frame: Up to Day 120

  34. Plasma Concentration of Anti-BIIB133 Antibodies

    Time frame: Up to Day 120

  35. Number of Participants with Anti-PEG Antibodies

    Time frame: Up to Day 120

  36. Plasma Concentration of Anti-PEG Antibodies

    Time frame: Up to Day 120

07

Study locations

1 site
  • Anaheim Clinical Trials
    Anaheim, California 92801, United States
08

References and documents

Individual participant data

Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2020 to primary completion in Apr 2021, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2020
First posted
Oct 1, 2020
StartActual
Oct 14, 2020
Primary completionActual
Apr 8, 2021
CompletionActual
Apr 8, 2021
Last update
Apr 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04571424
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Oct 1, 2020
Start date
Oct 14, 2020
Primary completion
Apr 8, 2021
Completion
Apr 8, 2021
Last update
Apr 18, 2023

Study contacts

Medical Director
study director · Biogen
Amina Haggag, M.D
principal investigator · Anaheim Clinical Trials

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapirolizumab pegol

Start the discussion